GlassScriptPhysician profile
Bruce Stephen Boliek
NPI 1033160817
$5,225.53
in general payments reported to CMS, 2019-2025
28 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $59.00 · 2021: $391 · 2022: $751 · 2023: $468 · 2024: $2,202 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,739 · Travel and Lodging: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,738.73 |
| Travel and Lodging | $791.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,698.31 | 2019-2025 | Lensx, Clareon Panoptix Pro, Rocklatan |
| Biotissue Holdings INC. | $565.31 | 2024-2025 | |
| Abbvie INC. | $194.40 | 2022-2025 | Vuity, Alphagan P, Lumigan |
| Johnson & Johnson Surgical Vision, INC. | $171.04 | 2024-2025 | Tecnis Simplicity |
| Tarsus Pharmaceuticals, INC. | $160.29 | 2024-2025 | Xdemvy |
| Allergan, INC. | $153.38 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $143.04 | 2019-2021 | |
| Ocular Therapeutix, INC. | $142.36 | 2021-2025 | Dextenza |
| Rxsight INC | $137.91 | 2022 | |
| Dompe US, INC. | $133.50 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $96.92 | 2022-2024 | Tyrvaya, Ryzumvi |
| Amgen INC. | $82.00 | 2024-2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $79.46 | 2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $64.97 | 2019-2021 | |
| Thea Pharma INC. | $59.23 | 2023-2024 | Iyuzeh |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $52.74 | 2022-2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $47.14 | 2023-2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Shire North American Group INC | $46.03 | 2019 | |
| Notal Vision, INC. | $32.77 | 2019-2025 | Foresee Home |
| Sun Pharmaceutical Industries INC. | $24.50 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.34 | 2025 | Acthar |
| Harrow Eye, LLC | $19.80 | 2024 | Vevye |
| Akorn, INC. | $19.28 | 2019 | |
| Bausch & Lomb Americas INC. | $18.78 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.05 | 2021 | |
| Omeros Corporation | $16.80 | 2021 | |
| Ivantis, INC | $14.83 | 2021 | |
| Sight Sciences, INC. | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Boliek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.